0.18
+1.12%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Celyad Oncology
Its shares trade on Euronext Brussels under the ticker CYAD.BR. It has been listed since 5 July 2013. In the fiscal year to 31 December 2025, it reported revenue of €21,000 and net income of €830,000. At that date it held total assets of €4.3m and shareholders' equity of €2.4m.
Celyad Oncology SA engages in the development of cell-based therapies for the treatment of cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon. The company went IPO on 2013-07-05. The firm develops stem cell-based therapies for cardiovascular disease. The firm focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The firm's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Jul 2013
- Employees
- 82
- Website
- celyad.com ↗
Leadership
Pay as last reported
- Ms. Hilde WindelsChairwoman of the Board, since 2018€63,000
- Mr. Matt KaneChief Executive Officer
- Mr. Philippe NobelsChief Human Resource Officer - Representative of MC Consult SRL, Member of the Executive Management Committee
- Mr. David GilhamChief Scientific Officer, Member of the Executive Management Committee
- Dr. Fredrik LehmannVice President Clinical Development and Medical Affairs - Representative of ImXense SRL, Member of the Executive Management Committee
- Dr. Charles MorrisChief Medical Officer
- Mr. Philippe DechampsChief Legal Officer, Corporate Secretary - Representative of NandaDevi SRL, Member of the Executive Management Committee
- Dr. Stephen RubinoChief Business Officer, Member of the Executive Management Committee
- Mr. Michel LussierDirector, since 2007€97,970
- Mr. Chris BuyseNon-Executive Director, since 2020€63,470
- Mr. Serge GobletNon-Executive Director€43,480
- Mr. Christopher Li PumaNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Celyad Oncology possesses several strengths that contribute to its competitive advantage in the oncology sector. These strengths include:
Weaknesses
- Despite its strengths, Celyad Oncology also faces certain weaknesses that may hinder its growth and market position. These weaknesses include:
Opportunities
- Celyad Oncology can capitalize on various opportunities within the oncology market to drive its growth and success. These opportunities include:
Threats
- Celyad Oncology also faces several threats that may pose challenges to its growth and sustainability. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.